Skip to Content
Merck
CN

P6402

Perphenazine

Synonym(s):

4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C21H26ClN3OS
CAS Number:
58-39-9
Molecular Weight:
403.97
NACRES:
NA.77
PubChem Substance ID:
24278642
UNSPSC Code:
12352200
EC Number:
200-381-5
MDL number:
MFCD00056798
Form:
powder
Quality level:
200

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

RGCVKNLCSQQDEP-UHFFFAOYSA-N

InChI

1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2

SMILES string

ClC(C=C1)=CC2=C1SC3=CC=CC=C3N2CCCN4CCN(CCO)CC4

form

powder

originator

Schering Plough

storage temp.

2-8°C

Quality Level

200

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRA2A(150), ADRA2B(151), ADRA2C(152), DRD2(1813), OPRS1(10280)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

D2 dopamine receptor antagonist; α-adrenergic receptor antagonist and σ-receptor agonist; phenothiazine antipsychotic. Inhibits glutamate dehydrogenase in vitro.

Features and Benefits

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

Perphenazine is an antipsychotic drug used in treating schizophrenia. It modulates antioxidant levels and helps in the management of oxidative injury in schizophrenia. However, it is less effective than the clozapine drug group in improving response to oxidative injury.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302,H317

Hazard Classifications

Acute Tox. 4 Oral - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCP4160
MKCN2541
MKCL7843
MKCJ3437
MKCG6835

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Angela M Koranek et al.
Schizophrenia research, 137(1-3), 137-140 (2012-03-01)
Results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) indicate that, with the exception of olanzapine, no substantial overall differences were identified between second generation antipsychotics (SGAs) and the first generation antipsychotic (FGA) perphenazine. This study evaluated the effect
Donald E Addington et al.
The Journal of clinical psychiatry, 72(1), 75-80 (2010-09-28)
According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the
Elina Turunen et al.
The Journal of pharmacy and pharmacology, 63(1), 19-25 (2010-12-16)
The sublingual administration route as well as solid dispersion formation with macrogol 8000 and complexation with β-cyclodextrin (β-CyD) were investigated as ways for improving the absorption of perphenazine, a poorly water-soluble drug subjected to substantial first-pass metabolism. The absorption of
Frank B Yoon et al.
Statistics in medicine, 30(16), 1917-1932 (2011-05-04)
In clinical trials multiple outcomes are often used to assess treatment interventions. This paper presents an evaluation of likelihood-based methods for jointly testing treatment effects in clinical trials with multiple continuous outcomes. Specifically, we compare the power of joint tests
Stanley N Caroff et al.
The Journal of clinical psychiatry, 72(3), 295-303 (2010-09-08)
We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD. This analysis compared 200 patients with DSM-IV-defined schizophrenia and TD and 997 patients without TD, all of whom were
View All Related Papers

Articles

Glutamine Metabolism in Cancer Cells

Sigma article discusses tumor cell metabolic pathways, focusing on aerobic glycolysis and mitochondrial activity.

许多癌细胞中的谷氨酰胺代谢失调

本文介绍了增殖活性细胞为何需要碳源和氮源合成大分子。尽管大部分肿瘤细胞利用有氧糖酵解途径并分流线粒体氧化磷酸化代谢物，但许多肿瘤细胞表现出线粒体活性增加。

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service